No profile data available.
Haleon plc (HLN) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Weybridge, United Kingdom, with about 24,535 full-time employees.
It reported revenue of 11.03 billion GBP for fiscal year 2025, down 1.8% from fiscal year 2024, and net income of 1.67 billion GBP. Its largest business segment, Europe, Middle East, Africa and Latin America, brought in 42% of segment revenue in fiscal year 2025; Rest of The World was the largest region with 56%. Its market capitalization was $40.99 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Haleon reported 11.03 billion GBP in revenue for fiscal year 2025, down 1.8% from 11.23 billion GBP in fiscal year 2024.
Europe, Middle East, Africa and Latin America, with 4.59 billion GBP or 42% of segment revenue in fiscal year 2025. Next: North America (35%) and Asia Pacific (23%).
Rest of The World: 56% of revenue by region in fiscal year 2025, followed by US & Puerto Rico (31%).
$40.99 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include GSK plc (GSK), Takeda Pharmaceutical Company Limited (TAK), Teva Pharmaceutical Industries Limited (TEVA), Royalty Pharma plc (RPRX).